Clinical validity of aDPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines-Reference-Cited by-同舟云学术

Clinical validity of aDPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines

Published:2015-07-14 Issue:12 Volume:137 Page:2971-2980
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Toffoli Giuseppe¹,Giodini Luciana¹,Buonadonna Angela²,Berretta Massimiliano³,De Paoli Antonino⁴,Scalone Simona²,Miolo Gianmaria²,Mini Enrico⁵,Nobili Stefania⁶,Lonardi Sara⁷,Pella Nicoletta⁸,Lo Re Giovanni⁹,Montico Marcella¹,Roncato Rossana¹,Dreussi Eva¹,Gagno Sara¹,Cecchin Erika¹

Affiliation:

1. Experimental and Clinical Pharmacology; Centro Di Riferimento Oncologico-National Cancer Institute; 2-33081 Aviano Italy

2. Medical Oncology Unit B; Centro Di Riferimento Oncologico-National Cancer Institute; 2-33081 Aviano Italy

3. Medical Oncology Unit A; Centro Di Riferimento Oncologico-National Cancer Institute; 2-33081 Aviano Italy

4. Department of Radiation Oncology; Centro Di Riferimento Oncologico-National Cancer Institute; 2-33081 Aviano Italy

5. Section of Internal Medicine; Department of Experimental and Clinical Medicine; University of Florence; 6-50139 Florence Italy

6. Section of Clinical Pharmacology and Oncology; Department of Health Sciences; University of Florence; 6-50139 Florence Italy

7. Medical Oncology Unit 1; Istituto Oncologico Veneto- IRCCS; 64-35128 Padua Italy

8. Medical Oncology Unit; University Hospital; 15-33100 Udine Italy

9. Oncology Unit; “Azienda Ospedaliera Santa Maria degli Angeli”; Pordenone Italy

Funder

“Associazione Italiana per la Ricerca sul Cancro” (AIRC) [Special Program Molecular Clinical Oncology, 5x1000]

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference37 articles.

1. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing;Caudle;Clin Pharmacol Ther,2013

2. Systemic therapy for colorectal cancer;Meyerhardt;N Engl J Med,2005

3. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS;Rosmarin;Gut,2015

4. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803;Saltz;J Clin Oncol,2007

5. dbSNP: the NCBI database of genetic variation;Sherry;Nucleic Acids Res,2001

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endogamy and high prevalence of deleterious mutations in India: evidence from strong founder events;2024-08-29

2. MIR27A Gene Polymorphism Modifies the Effect of Common DPYD Gene Variants on Severe Toxicity in Patients with Gastrointestinal Tumors Treated with Fluoropyrimidine-Based Anticancer Therapy;International Journal of Molecular Sciences;2024-08-04

3. Improving single nucleotide polymorphisms genotyping accuracy for dihydropyrimidine dehydrogenase testing in pharmacogenetics;Exploration of Targeted Anti-tumor Therapy;2024-04-24

4. Clinical Implementation of Rare and Novel DPYD Variants for Personalizing Fluoropyrimidine Treatment: Challenges and Opportunities;International Journal of Biological Sciences;2024

5. Implementation of pre‐emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?;British Journal of Clinical Pharmacology;2023-12-21